Nani Draman, Nazri Mustaffa, PM Zurkurnai Yusof

The Effect of Add-On Rosiglitazone

on the Ankle-Brachial Pressure Index of Patients With Type 2 Diabetes Mellitus in Husm, Malaysia

• Broschiertes Buch

Produktbeschreibung

Rosiglitazone, an oral hypoglycaemic agent of the thiazolidinedione group is used for Type 2 Diabetes treatment. Research has shown that this medication, being a peroxisome proliferator activator receptor-gamma agonist has effects beyond glycaemic control alone. Apart from improving insulin resistance, the non-hypoglycaemic effects of rosiglitazone include reduction of inflammatory markers, improvement of endothelial function, improvement in fibrinolytic activity as well as changes in cholesterol profile. This study aims to assess changes in surrogate markers of atherosclerotic burden via ankle-brachial pressure index measurements, the number of patients who have significant peripheral artery disease in the study, changes in the diabetic prothrombotic state via serum plasminogen activity, changes in glycaemic control via HbA1c and changes in cholesterol profile by measuring total-, high density lipoprotein- and low density lipoprotein-cholesterol after rosiglitazone is added to apre-existing Type 2 Diabetes treatment regime.

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Aufl.
• Seitenzahl: 88
• Englisch
• ISBN-13: 9783847375067
• ISBN-10: 3847375067
• Artikelnr.: 34876323

Autorenporträt

Dr. Nani Draman obtained her MD (1998) from Universiti Sains Malaysia and completed her Master of Medicine (Family Medicine) in 2009 from the same university. Currently she is a lecturer in Family Medicine Department , School of Medical Sciences, USM with special interest in Diabetes Mellitus and CVD disease.